What Researchers Did
US researchers reviewed the pre-clinical and clinical evidence for HBOT as a treatment and preconditioning strategy for acute ischemic stroke, focusing on its effects on oxidative stress, inflammation, and neuroprotection.
What They Found
Pre-clinical evidence shows HBOT reduces oxidative stress, neuroinflammation, and cell death after stroke, improving functional recovery in animal models. Early clinical studies suggest benefit when started within the therapeutic window, and HBOT preconditioning, using mild oxidative stress to prime the brain, has shown promise in establishing ischemic tolerance. Combining HBOT with stem cell therapy is also discussed as an emerging strategy.
What This Means for Canadian Patients
Stroke is a leading cause of disability among Canadians. While HBOT is not yet a standard treatment for ischemic stroke in Canada, the growing pre-clinical evidence suggests it merits evaluation in Canadian clinical trials.
Canadian Relevance
No direct Canadian connection identified. Stroke is a major cause of death and disability in Canada, affecting roughly 62,000 Canadians annually, so advances in neuroprotective treatment are directly relevant.
Study Limitations
This is a narrative review of animal and early clinical studies; the evidence base for clinical use in human stroke is not yet sufficient for standard-of-care recommendations.